COMMUNIQUÉS West-GlobeNewswire

-
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
01/06/2024 -
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
01/06/2024 -
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
31/05/2024 -
RYBREVANT®▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
31/05/2024 -
Mainz Biomed Reports Results of 2024 Annual General Meeting
31/05/2024 -
Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
31/05/2024 -
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
31/05/2024 -
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to July 3, 2024
31/05/2024 -
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31/05/2024 -
Fortrea lance une solution complète pour améliorer la diversité et l’inclusion dans la recherche clinique
31/05/2024 -
EAACI Congress Kicks Off in Valencia, Spain
31/05/2024 -
Smart for Life to be Featured in Whole Foods Magazine Highlighting Product Offerings, Strategic Acquisitions and Expansion Initiatives
31/05/2024 -
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
31/05/2024 -
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
31/05/2024 -
Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le marché en Europe de son vaccin contre le chikungunya
31/05/2024 -
OPKO Health to Participate in the Jefferies Global Healthcare Conference
31/05/2024 -
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
31/05/2024 -
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31/05/2024 -
AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
31/05/2024
Pages